文献速递头颈外科

转移性口咽癌的放疗:基于NCDB的生存分析

Radiotherapy in Metastatic Oropharyngeal Cancer.
PubMed 文献 · Laryngoscope · 2020-11-03

本研究利用美国国家癌症数据库(NCDB)2004–2015年数据,分析接受全身治疗的初诊转移性口咽鳞癌患者中,头颈部放疗与总生存的关联。在556例已知HPV状态的患者中,49%为HPV阳性,56%接受了头颈部放疗;中位随访17.5个月,放疗与1年OS显著改善相关(67% vs 58%,P < .001),多因素分析HR 0.78(95%CI 0.62–0.97,P = .029)。HPV阳性亚组可见生存获益(1年OS 77% vs 67%,P < .001),HPV阴性患者未见获益;倾向性评分匹配的212例HPV阳性患者中HR 0.66(95%CI 0.49–0.83,P < .001)。

要点

  • 转移性口咽癌接受全身治疗者中,头颈部放疗与1年OS改善相关(67% vs 58%)。
  • 生存获益主要见于HPV阳性患者,HPV阴性患者未见显著获益。
  • 倾向性评分匹配后HPV阳性患者放疗获益仍显著(HR 0.66)。

核心结论

  • 在已知HPV状态的转移性口咽鳞癌患者中,头颈部放疗与HPV相关疾病患者更长的生存相关。

研究设计与样本

  • 回顾性队列研究,查询NCDB 2004–2015年数据,纳入初诊转移且接受全身治疗的口咽鳞癌患者。
  • 共2139例转移性口咽鳞癌接受全身治疗,其中556例已知HPV状态纳入分析。

主要发现

  • 556例中49%为HPV阳性,56%接受了头颈部放疗。
  • 中位随访17.5个月(IQR 6.0–163.4个月),放疗组1年OS为67%,非放疗组为58%(log-rank P < .001)。
  • 多因素分析显示放疗与OS改善独立相关(HR 0.78,95%CI 0.62–0.97,P = .029)。
  • HPV阳性亚组1年OS为77% vs 67%(log-rank P < .001),HPV阴性患者未见生存获益。
  • 倾向性评分匹配的212例HPV阳性患者中,放疗与OS改善相关(HR 0.66,95%CI 0.49–0.83,P < .001)。

临床怎么用

  • 对于接受全身治疗的转移性口咽鳞癌患者,尤其是HPV阳性者,可考虑联合头颈部放疗以改善生存。

局限性

  • 研究为回顾性数据库分析,证据等级为3级。
  • 仅556例已知HPV状态,存在选择偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The role of locoregional radiotherapy for metastatic oropharyngeal squamous cell cancer (OPSCC) is unclear. We investigated the impact of head and neck radiotherapy on survival in de novo metastatic OPSCC patients who received systemic therapy. METHODS: We queried the NCDB from 2004-2015 for metastatic OPSCC patients at diagnosis with known HPV-status who received systemic therapy. The association of head and neck radiotherapy with overall survival was analyzed using the Kaplan-Meier method, Cox proportional hazards model, and propensity score-matched analysis adjusting for demographic and disease-specific prognostic factors. RESULTS: Of the 2,139 patients with metastatic OPSCC who presented with metastases and received systemic treatment, we identified 556 patients with known HPV-status. Among these 556 patients, 49% were HPV-positive and 56% received head and neck radiotherapy. With a median follow-up of 17.5 months (IQR 6.0-163.4 months), radiotherapy was associated with significantly improved 1-year OS (67% vs 58%, log-rank P < .001) which remained significant on MVA (HR 0.78 95% CI 0.62-0.97 P = .029). In HPV-status subgroup analysis, a survival benefit was identified in HPV-positive patients (1-year OS 77% vs 67%, log-rank P < .001) but not in HPV-negative patients. Results were consistent on a propensity score-matched analysis of 212 HPV-positive matched patients (HR 0.66, 95% CI 0.49-0.83, P < .001). CONCLUSION: The survival of metastatic OPSCC remains limited. In this large series of patients with known HPV-status, head and neck radiotherapy was associated with longer survival in those with HPV-associated disease. These data could guide management of this challenging group of patients for head and neck cancer practitioners. LEVEL OF EVIDENCE: 3 Laryngoscope, 131:E1847-E1853, 2021.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Nguy S, Oh C, Karp JM, et al. Radiotherapy in Metastatic Oropharyngeal Cancer. Laryngoscope. 2020. PMID: 33141455. doi:10.1002/lary.29245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。